Comparison of standard fibrinogen measurement methods with fibrin clot firmness assessed by thromboelastometry in patients with cirrhosis.

Abstract:

BACKGROUND:The Clauss fibrinogen method and thrombin clotting time (TCT) are still routinely used in patients with cirrhosis to define fibrinogen concentration and clotting potential. The thromboelastometric functional fibrinogen FIBTEM assay evaluates the strength of fibrin-based clots in whole blood, providing information on both quantitative deficit and fibrin polymerization disorders. OBJECTIVE:To compare these three methods of assessing fibrinogen in patients with cirrhosis of different aetiologies, characterized by impairment in fibrinogen concentration as well as functional aberrance. METHODS:Sixty patients with alcoholic and 24 patients with cholestatic cirrhosis were included (Child-Pugh score (CPs)A, n=24; B, n=32; C, n=28). All parameters were compared with those from a control group. Maximum clot firmness (MCF) in the FIBTEM test was assessed in regard to its relevance in detection of qualitative fibrinogen disorders in comparison with results obtained by standard measurement methods, i.e. the Clauss fibrinogen method and TCT. RESULTS:With increased cirrhosis severity, fibrinogen and FIBTEM-MCF levels significantly declined (p=0.002), while TCT was significantly prolonged (p=0.002). In all CPs groups, fibrinogen strongly correlated with FIBTEM-MCF (r=0.77, r=0.72, r=0.74; p<0.001), while cross-correlations of other assays were highly variable. The prevalence of decreased FIBTEM-MCF values (<9 mm) was significantly higher in advanced CPs categories (p=0.027), whereby the highest prevalence was detected in patients with CPsC (10/16; 62.5%). Nine of the 16 patients with decreased FIBTEM-MCF values had also decreased fibrinogen levels, while in the remaining 7 patients fibrinogen levels were within the reference range, indicating the possible presence of qualitatively altered fibrinogen that could be detected by FIBTEM-MCF. CONCLUSIONS:FIBTEM-MCF may be considered as a reliable alternative to standard plasma fibrinogen measurement in cirrhotic patients, especially in evaluating fibrin polymerization disorders in these patients. Further studies are needed to evaluate the usefulness of this assay in predicting bleeding complications in cirrhotic patients as well as monitoring replacement treatment.

journal_name

Thromb Res

journal_title

Thrombosis research

authors

Vucelic D,Jesic R,Jovicic S,Zivotic M,Grubor N,Trajkovic G,Canic I,Elezovic I,Antovic A

doi

10.1016/j.thromres.2015.04.003

subject

Has Abstract

pub_date

2015-06-01 00:00:00

pages

1124-30

issue

6

eissn

0049-3848

issn

1879-2472

pii

S0049-3848(15)00158-9

journal_volume

135

pub_type

杂志文章
  • Induction of tissue factor-like activity of human monoblastic leukemia cell line by tumor necrosis factor-alpha.

    abstract::Cell lysates of the human monoblastic leukemia cell line, THP-1, have procoagulant activity (PCA) that is Ca++-dependent and not demonstrable in either Factor VII-, or Factor X-deficient plasma. The PCA of THP-1 cells was enhanced by human recombinant tumor necrosis factor-alpha (TNF-alpha) up to five fold. There was ...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/0049-3848(89)90162-x

    authors: Tanaka M

    更新日期:1989-10-15 00:00:00

  • Evaluation of anti-platelet and anti-thrombotic effects of cilostazol with PFA-100® and Multiplate® whole blood aggregometer in vitro, ex vivo and FeCl3-induced thrombosis models in vivo.

    abstract::We evaluate the anti-platelet and anti-thrombotic effects of cilostazol using Multiplate® and PFA-100® in vitro and ex vivo with freshly isolated rat whole blood and in vivo venous and arterial thrombosis models in the same species, in an effort to assess the sensitivity of the whole blood aggregometer assays without ...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/j.thromres.2011.02.004

    authors: Kim CW,Yun JW,Bae IH,Park YH,Jeong YS,Park JW,Chung JH,Park YH,Lim KM

    更新日期:2011-06-01 00:00:00

  • N' alkylamine low molecular mass heparins (LMM-heparin-tyramine and LMM-heparin-tyramine-fitc) exhibit long lasting anticoagulant effects.

    abstract::The pharmacodynamic and pharmacokinetic properties of endpoint-attached N'alkylamine derivatives of low molecular mass heparin (LMMH), low molecular mass heparin (LMMH), low molecular mass heparin-tyramine (LMMH-tyr) and low molecular mass heparin-tyramine-fluorescein-5-isothiocyanate (LMMH-tyr-fitc) were investigated...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/0049-3848(95)00172-n

    authors: Malsch R,Piazolo L,Harenberg J,Heene DL

    更新日期:1995-11-01 00:00:00

  • Biological effect of increased maintenance dose of clopidogrel in cardiovascular outpatients and influence of the cytochrome P450 2C19*2 allele on clopidogrel responsiveness.

    abstract:INTRODUCTION:The first aim of this study is to evaluate the biological effect of doubling the maintenance dose of clopidogrel in pre-defined clopidogrel "low responders", compared to the biological effect of the standard dose in "responders". The second aim is to test the influence of the CYP 2C19*2 allele on clopidogr...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/j.thromres.2007.06.012

    authors: Fontana P,Senouf D,Mach F

    更新日期:2008-01-01 00:00:00

  • Antithrombotic and anticomplementary properties of a very low molecular mass dermatan sulfate.

    abstract:INTRODUCTION:Dermatan sulfate, a sulfated glycosaminoglycan, acts as an anticoagulant by accelerating the inhibition of thrombin by heparin cofactor II. MATERIALS AND METHODS:A low molecular mass dermatan sulfate was obtained by peroxy-radical depolymerization from a parent dermatan sulfate. Chemical characterization ...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/j.thromres.2007.09.001

    authors: Fabiana Alberto M,Giaquinta Romero D,Lazzari M,Calabrese GC

    更新日期:2008-01-01 00:00:00

  • Prostacyclin potentiates 13-azaprostanoic acid-induced platelet deaggregation.

    abstract::The specific thromboxane A2/prostaglandin H2 (TXA2/PGH2) antagonist 13-azaprostanoic acid (13-APA) reverses platelet aggregation stimulated by TXA2/PGH2 and the prostaglandin endoperoxide analog U46619. The present report demonstrates that the deaggregatory properties of 13-APA are potentiated by prostacyclin (PGI2). ...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/0049-3848(82)90097-4

    authors: Parise LV,Venton DL,Le Breton GC

    更新日期:1982-12-15 00:00:00

  • Monitoring treatments with unfractionated heparin: CTAD must be used instead of citrate as the anticoagulant solution when using partial-draw collection tubes. Results of a multicenter evaluation.

    abstract:BACKGROUND:Sampling small volumes of blood may be necessary, particularly in pediatric patients, or in case of difficult or recurrent venipunctures. METHODS:Routine hemostasis test results evaluated in partial- and full-draw evacuated polymer tubes obtained in 4 centers were compared. RESULTS:No relevant discrepancy ...

    journal_title:Thrombosis research

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.thromres.2010.08.029

    authors: Toulon P,Abecassis L,Smahi M,Ternisien C

    更新日期:2010-12-01 00:00:00

  • Effects of balanced hydroxyethyl starch 6% (130/0.4) and albumin 5% on clot formation and glycocalyx shedding: Subgroup analysis of a prospective randomized trial.

    abstract:BACKGROUND:Intravenous fluids can impair coagulation and affect the endothelial glycocalyx, whereas glycocalyx shedding itself can cause an impairment of clot formation and firmness. We hypothesized that hydroxyethyl starch 6% (130/0.4) has a more distinct effect on coagulation and glycocalyx shedding than albumin 5%. ...

    journal_title:Thrombosis research

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.thromres.2019.10.020

    authors: Kammerer T,Hulde N,Speck E,Hübner M,Crispin A,Zwissler B,Conzen P,von Dossow V,Schäfer ST,Hofmann-Kiefer K,Rehm M

    更新日期:2019-11-01 00:00:00

  • Cilostazol for primary prevention of stroke in peripheral artery disease: a population-based longitudinal study in Taiwan.

    abstract:BACKGROUND:Clopidogrel, cilostazol, and aspirin were compared in terms of efficacy and safety for primary prevention of stroke in peripheral artery disease (PAD) patients. METHODS:This retrospective cohort study analyzed data contained in the Taiwan National Health Insurance Bureau database for patients treated for PA...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/j.thromres.2013.01.036

    authors: Lee WH,Chu CY,Hsu PC,Su HM,Lin TH,Voon WC,Lai WT,Sheu SH

    更新日期:2013-08-01 00:00:00

  • Analysis of antithrombin III microheterogeneity by isoelectric focusing in polyacrylamide gels and immunoblotting.

    abstract::Microheterogeneity of antithrombin III (ATIII) was examined in pooled normal human plasma and serum by IEF/PA and immunoblotting techniques. A pattern consisting of 8 bands varying in isoelectric point from 4.7 to 5.2 was observed in citrated plasma following IEF in a pH range of 4-6. A similar pattern was observed in...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/0049-3848(85)90331-7

    authors: Daly M,Hallinan F

    更新日期:1985-10-15 00:00:00

  • Thrombosis in VonWillebrand disease.

    abstract:OBJECTIVE:To date, only a few case studies have reported occurrence of thrombosis in patients with VonWillebrand disease (VWD). No studies have looked at its incidence in this patient population. The aim of this study was to test our hypothesis that decreased VonWillebrand factor (VWF) levels confer a protective effect...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/j.thromres.2012.09.005

    authors: Qureshi W,Hassan S,Dabak V,Kuriakose P

    更新日期:2012-11-01 00:00:00

  • Detection of hypofibrinolysis in stable coronary artery disease using the overall haemostatic potential assay.

    abstract:INTRODUCTION:Patients with stable coronary artery disease (CAD) are at risk of arterial thrombosis causing myocardial infarction. Detection of global haemostatic markers of hypercoagulability and hypofibrinolysis may be important for risk stratification and individualised treatment. We examined overall haemostatic pote...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/j.thromres.2013.03.015

    authors: Reddel CJ,Curnow JL,Voitl J,Rosenov A,Pennings GJ,Morel-Kopp MC,Brieger DB

    更新日期:2013-05-01 00:00:00

  • Antithrombotic effects of aspirin based on PLA1/A2 glycoprotein IIIa polymorphism in patients with coronary artery disease.

    abstract:OBJECTIVE:The diallelic glycoprotein IIIa polymorphism P1A1/A2 was attributed to be an inherited risk factor for coronary events. Whether this polymorphism affects response to aspirin in patients with coronary artery disease is not known. METHODS:We assessed thrombin generation (prothrombin fragment F1+2) in consecuti...

    journal_title:Thrombosis research

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.thromres.2006.03.005

    authors: Dropinski J,Musial J,Sanak M,Wegrzyn W,Nizankowski R,Szczeklik A

    更新日期:2007-01-01 00:00:00

  • Antithrombin III deficiency as a risk factor for catheter-related central vein thrombosis in cancer patients.

    abstract::The fibrin sleeve of venous catheters (VC) and parietal thrombi represent frequent and dangerous side-effects of central venous catheterization (CVC), due to the risk of embolism. Reduced levels of coagulation clotting factors inhibitors (such as Antithrombin III) are known to be associated with increased thrombogenic...

    journal_title:Thrombosis research

    pub_type: 临床试验,杂志文章

    doi:10.1016/0049-3848(95)00041-0

    authors: De Cicco M,Matovic M,Balestreri L,De Angelis V,Fracasso A,Morassut S,Coran F,Babare R,Buonadonna A,Testa V

    更新日期:1995-04-15 00:00:00

  • Correlation of coagulation markers and 4F-PCC-mediated reversal of rivaroxaban in a rabbit model of acute bleeding.

    abstract:INTRODUCTION:Rivaroxaban is an oral, selective direct factor Xa inhibitor approved for several indications in patients at risk of thrombotic events. One limitation of its clinical use is the lack of data pertaining to its reversal in situations where urgent response is critical (e.g. acute bleeding events or emergency ...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/j.thromres.2015.01.007

    authors: Herzog E,Kaspereit F,Krege W,Mueller-Cohrs J,Doerr B,Niebl P,Dickneite G

    更新日期:2015-03-01 00:00:00

  • Risk of deep venous thrombosis (DVT) in bedridden or wheelchair-bound multiple sclerosis patients: a prospective study.

    abstract:BACKGROUND:Multiple sclerosis (MS) often causes progressive loss of mobility, leading to limb paralysis. Venous and lymphatic stasis is a risk condition for venous thromboembolism (VTE). There is, however, no data on the frequency of VTE complicating the progression of MS. The aim of this study was to assess the freque...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/j.thromres.2009.06.023

    authors: Arpaia G,Bavera PM,Caputo D,Mendozzi L,Cavarretta R,Agus GB,Milani M,Ippolito E,Cimminiello C

    更新日期:2010-04-01 00:00:00

  • MiR-188-3p upregulation results in the inhibition of macrophage proinflammatory activities and atherosclerosis in ApoE-deficient mice.

    abstract:BACKGROUND:Atherosclerosis occurs as a result of a chronic inflammatory response in the arterial wall associated with an increased uptake of low-density lipoprotein by macrophages and the subsequent transformation of this lipoprotein into foam cells. It has been found that miR-188-3p can suppress autophagy and myocardi...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/j.thromres.2018.09.043

    authors: Zhang XF,Yang Y,Yang XY,Tong Q

    更新日期:2018-11-01 00:00:00

  • Tinzaparin in cancer associated thrombosis beyond 6months: TiCAT study.

    abstract:INTRODUCTION:The safety and efficacy of low-molecular-weight heparin (LMWH) treatment in patients with cancer-associated thrombosis (CAT) beyond 6months are unknown. Our aim was to determine the safety of long-term tinzaparin use in patients with CAT. METHODS:We performed a prospective, open, single arm, multicentre s...

    journal_title:Thrombosis research

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.thromres.2017.07.004

    authors: Jara-Palomares L,Solier-Lopez A,Elias-Hernandez T,Asensio-Cruz M,Blasco-Esquivias I,Marin-Barrera L,de la Borbolla-Artacho MR,Praena-Fernandez JM,Montero-Romero E,Navarro-Herrero S,Serrano-Gotarredona MP,Sánchez-Díaz JM,Palacios

    更新日期:2017-09-01 00:00:00

  • Release of tissue-type plasminogen activator (t-PA) in the splanchnic circulation of the anaesthetised pig during high sympathetic tone.

    abstract:BACKGROUND:There is a substantial local release of tissue-type plasminogen activator (t-PA) in the splanchnic vascular bed, and this release is increased at high sympathetic tone. Coronary t-PA release is also significant, and this release increases during cardiac nerve stimulation and during reperfusion after 10 min o...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/j.thromres.2009.10.004

    authors: Björkman JA,Ilebekk A,Jern C

    更新日期:2010-03-01 00:00:00

  • Intracranial subdural hematomas with elevated rivaroxaban concentration and subsequently detected spinal subdural hematoma: A case report.

    abstract::A 79-year-old lean man with a height of 157cm and weight of 42kg (body mass index, 17.2kg/m(2)) receiving rivaroxaban developed an intracranial subdural hematoma and was treated conservatively. Because he had a reduced creatinine clearance of 44mL/min, his dosage of rivaroxaban was reduced from 15 to 10mg daily accord...

    journal_title:Thrombosis research

    pub_type: 信件

    doi:10.1016/j.thromres.2016.05.020

    authors: Yamaguchi Y,Koga M,Matsuki T,Hino T,Yokota C,Toyoda K

    更新日期:2016-07-01 00:00:00

  • The role of biomarkers of endothelial activation in predicting morbidity and mortality in patients with severe sepsis and septic shock in intensive care: A prospective observational study.

    abstract:INTRODUCTION:Endothelial dysfunction plays an essential role in the pathogenesis of sepsis. The study aimed to illustrate the associations between the dynamic change (from day 1 to day 7) in biomarker concentration of endothelial dysfunction and outcomes in severe sepsis and septic shock in the intensive care unit (ICU...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/j.thromres.2018.09.059

    authors: Fang Y,Li C,Shao R,Yu H,Zhang Q

    更新日期:2018-11-01 00:00:00

  • Fondaparinux versus nadroparin for thromboprophylaxis following minimally invasive esophagectomy: A randomized controlled trial.

    abstract:BACKGROUND:The methodology of thromboprophylaxis post minimally invasive esophagectomy (MIE) is unclear. Thus, we compared the efficacy and safety of fondaparinux and nadroparin on the prophylaxis of venous thromboembolism (VTE) after MIE. MATERIALS AND METHODS:We conducted a randomized, double-blind, treatment-contro...

    journal_title:Thrombosis research

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.thromres.2018.04.001

    authors: Song J,Xuan L,Wu W,Shen Y,Tan L,Zhong M

    更新日期:2018-06-01 00:00:00

  • Variations of prothrombin time and international normalized ratio in patients treated with warfarin.

    abstract::Prothrombin time is a standard screening test to monitor patients treated with oral anticoagulants. We hypothesize that INR measurements will not vary a lot within a given day in a given patient. The present study was thus conducted to compare the change of the international normalized ratio (INR) of prothrombin time ...

    journal_title:Thrombosis research

    pub_type: 临床试验,杂志文章

    doi:10.1016/s0049-3848(02)00339-0

    authors: Ho CH,Lin MW,You JY,Chen CC,Yu TJ

    更新日期:2002-09-01 00:00:00

  • Old and new heparins.

    abstract::Heparin is an effective, relatively safe, inexpensive parenteral antithrombotic agent widely used in the prevention and treatment of thromboembolic disorders, but it has several limitations such as the marked intra- and inter-patient variability in its anticoagulant response, its poor bioavailability at low doses and ...

    journal_title:Thrombosis research

    pub_type: 杂志文章,评审

    doi:10.1016/j.thromres.2011.11.008

    authors: Cosmi B,Palareti G

    更新日期:2012-03-01 00:00:00

  • Impact of atrial fibrillation/flutter on the in-hospital mortality of surgical patients - Results from the German nationwide cohort.

    abstract:BACKGROUND:To investigate the impact of atrial fibrillation/flutter (AF) on adverse in-hospital outcomes in hospitalized surgical patients. METHODS:The nationwide German inpatient sample of the years 2005-2018 was used for this analysis. Surgical patients were stratified by AF and compared. Logistic regression models ...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/j.thromres.2020.10.015

    authors: Keller K,Hobohm L,Engelhardt M

    更新日期:2020-12-01 00:00:00

  • Discovering novel risk factors for venous thrombosis: a candidate-gene approach.

    abstract::The candidate-gene approach can be used to locate and identify genetic variations that are associated with a particular phenotype. This gene-centric approach assumes that there exists important genetic variation within genes that can influence health. Identifying known genes which are candidates for the phenotype of i...

    journal_title:Thrombosis research

    pub_type: 杂志文章,评审

    doi:10.1016/S0049-3848(09)70139-2

    authors: Smith NL,Rice KM,Lumley T,Heckbert SR,Psaty BM

    更新日期:2009-01-01 00:00:00

  • Association between red cell distribution width and risk of venous thromboembolism.

    abstract:BACKGROUND:An association between high red cell distribution width (RDW) and venous thromboembolism (VTE) has been observed. However, it is not known whether this association differs within various manifestations of VTE, nor if there is an interaction between RDW and thrombophilia abnormalities on the risk of VTE. AIM...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/j.thromres.2015.07.020

    authors: Bucciarelli P,Maino A,Felicetta I,Abbattista M,Passamonti SM,Artoni A,Martinelli I

    更新日期:2015-09-01 00:00:00

  • Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting.

    abstract:BACKGROUND:Although patients undergoing coronary stenting routinely receive dual antiplatelet treatment to reduce the risk of stent thrombosis, this undesired event still occurs. A suboptimal response to clopidogrel treatment (low responders) has been suggested to contribute to stent thrombosis. In the present study, p...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/j.thromres.2004.07.007

    authors: Angiolillo DJ,Fernandez-Ortiz A,Bernardo E,Ramírez C,Barrera-Ramirez C,Sabaté M,Hernández R,Moreno R,Escaned J,Alfonso F,Bañuelos C,Costa MA,Bass TA,Macaya C

    更新日期:2005-01-01 00:00:00

  • Determination of dabigatran and rivaroxaban by ultra-performance liquid chromatography-tandem mass spectrometry and coagulation assays after major orthopaedic surgery.

    abstract::Major orthopaedic surgery is associated with an increased risk of venous thromboembolism. Direct oral anticoagulants (DOACs) are recommended as thromboprophylactic agents after orthopaedic surgery. Although routine monitoring of DOACs in general is not required, measuring DOAC concentration may be necessary in clinica...

    journal_title:Thrombosis research

    pub_type: 临床试验,杂志文章

    doi:10.1016/j.thromres.2016.01.012

    authors: Schellings MW,Boonen K,Schmitz EM,Jonkers F,van den Heuvel DJ,Besselaar A,Hendriks JG,van de Kerkhof D

    更新日期:2016-03-01 00:00:00

  • Economic evaluation of rFVIIa high initial dose compared to rFVIIa standard initial dose in patients with haemophilia with inhibitors using the Czech HemoRec registry.

    abstract:INTRODUCTION:In the treatment of bleeds in haemophilia patients with inhibitors, a high initial dose of recombinant Factor VIIa (rFVIIa) provides at least equal efficacy and a similar safety profile to a standard initial dose. However, no pharmacoeconomic comparison between these dosing regimens has previously been per...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/j.thromres.2013.11.002

    authors: Salaj P,Kubes R,Cetkovsky P,Capova I,Penka M,Ovesná P,Mesterton J,Lindgren P

    更新日期:2014-02-01 00:00:00